AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE
AgNovos Bioscience announces that more than 150 patients have been enrolled in the RESTORE randomized, controlled trial of AGN1 LOEP.
Keep up to date on AgNovos events and related news
AgNovos Healthcare will once again attend WCO.
AgNovos Healthcare will exhibit at the Alterstraumatologie Kongress in Zürich and hold a symposium on the 22nd March.
During Alterstramatologie congress, Dr. Christian Fang presented a poster featuring the interim results of the ongoing STRONG clinical study.
At the ORS 2018 Annual Meeting in New Orleans, Dr. Jonathan Shaul (PhD), AgNovos Sr. Research Engineer, was selected as a finalist for both the New Investigator Recognition Award (NIRA) and ORS Preclinical Models Section Member Podium Award for his presentation: "Injectable Triphasic Biomaterial Resorbs and Increases Bone Formation in Ovariectomized Rat Metaphyseal Defects of the Femur".
AgNovos Healthcare is pleased to announce that it has hired Falk Dukatz as Vice President of Global Sales.
During the Ortomed Conference in Florence, Italy, Dr. James Howe will present the rationale and the science supporting OSSURE LOEP (Local Osteo-Enhancement Procedure), an emerging treatment for osteoporosis-related bone loss in the proximal femur.